IBB breaking out. Not very bright being short here but we new that at 6 bucks where mathew,n16, moe and pokerhead took there position
IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL
MarketCap $46 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.70
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
Monster MicroCaps SPECIAL ALERT to FOLD shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market. https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html
NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
Good chance for $10 this week .
FOLD, OMER, PLX - great science with huge upside. Longs will be rewarded. Just patience which is very important in Biotech industry
37.6 million short shares at 8.50 or MUCH less and it can't go past $10?? Lol, that's funny
Wow the rookies are awful quiet. Mathspew, Moeron and n15dik must be taking small change for favors in Chicago in order to cover their margin calls.
What really makes me laugh is not only that FOLD is hitting their stride with products but the IBB is breaking out after a two year beat down. Lots of shorts out there who are too stupid to understand that we will be at 15 by Labor Day and most likely before it. Man this is fun!
Close above 9.92 and we go much higher, IMO.
Close to 800,000 shares in the first hour and over 10 is an encouraging signal. 6/20, Tuesday..
Let me repeat. Crowley has given ZERO updates on the Japan NDA filing. He has only ONE (1) week left to fulfill the promise that he made to investors of filing the NDA. Even at that it won't be approved and ready for scripts for AT LEAST 13 months if not longer. Crowley is hammering this companies revenue into a coffin!! Don't be deceived
Let's not forget just how bad bios have been for the last 2 years. If we get money flows back into the sector, it will be a true blast higher.
To the shorts like mathew n16 and the poker knucklehead, Why would anyone bet against a biotech who is trying to save lives? You must be hillary fans. It's just plain low.
Never bet against a man who is trying to save his children, like Crowley.
It's highly suspect that Crowley has given ZERO updates on the Japan NDA filing. Can we expect a good 30% drop when the news breaks they will wait for the additional clinical trial to complete as required by the FDA?
Harry Boxer has posted his Charts of the Day video on FOLD at TheTechTrader site noting: Amicus Therapeutics, Inc. (FOLD), one of our recent new swings, popped three days ago, consolidated, and popped again on Wednesday, up 39 cents, or 4%, to 9.94, on 4.5 million shares traded. If it gets through 10.20, it could accelerate to the 11.50-12.00 range.
Ready for the dilution? Just watch.
John Crowley on EB program, Goldman Sachs presentation. -Most devastating rare disease he had ever seen. It is like children living with a 3d degree burn for the whole life. -A lot of interest from European companies. -Think about using Zorblista in much more prevalent skin disorders. If Zorblista works in a such severe skin disease as EB, it definitely has a good chance to work in many other indications.
Blowoff top followed by the dilution crater. MASSIVE shares out and going higher and MASSIVE losses forever.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.1 In other words, the correlation coefficient of the other stoc
Don't get too excited. Analysts are showing a 0.99 loss in 2018.